Multitude Therapeutics Inc.

No. 159 Tianzhou Road, Xuhui District, Shanghai, China

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

75.0%

Phase 2

25.0%

Trial Status Distribution

Not yet recruiting

12.5%

Recruiting

87.5%

Clinical Trials

Trials sponsored by this organization (8)

Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Phase 2

Not yet recruiting

interventional

Aug 2026512 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations

Multitude Therapeutics Inc.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (8)

Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

AMT-116 in Combination With AK112 in Patients With Lung Cancer

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

AMT-676 in Patients With Advanced Solid Tumors

AMT-116 in Patients with Solid Tumors

AMT-253 in Patients With Advanced Solid Tumours

AMT-116 in Patients With Advanced Solid Tumors

AMT-151 in Patients With Selected Advanced Solid Tumours

Approvals

News